Drug Profile
AAV1-gSG
Alternative Names: AAV1-gamma-sarcoglycan gene therapy - Genethon; AAV1-gamma-sarcoglycan vector injection - Genethon; Adeno-associated viral 1 vector-mediated gamma-sarcoglycan gene therapy - Genethon; Adeno-associated viral vector containing the human gamma-sarcoglycan gene - Genethon; Adeno-associated virus 1-gamma-sarcoglycan gene therapy - Genethon; Gamma sarcoglycanopathy gene therapy - GenethonLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator ViroMed Co Ltd
- Developer Genethon
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sarcoglycanopathies
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Sarcoglycanopathies in France (IV)
- 23 Feb 2023 Discontinued - Preclinical for Sarcoglycanopathies in USA (IM)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Sarcoglycanopathies in France (IM, Injection)